Cambridge, UK – October 26th - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has today announced that its Clinical Laboratory Division has extended its Clinical Pathology Accreditation (CPA) scope to include Molecular Biology and Virology in addition to Biochemistry.
The accreditation was awarded by Clinical Pathology Accreditation (UK), the quality assurance agency that verifies the quality compliance of the UK’s NHS and private sector laboratories.
Lab21’s Clinical Laboratory, which is based in Cambridge, performs molecular diagnostic testing in Oncology, HIV and Hepatitis with a focus on therapy management enabling health professionals to improve outcomes for their patients. Customers include NHS hospitals, private sector clinics and pharmaceutical companies across the globe.
This latest accreditation builds on Lab21’s existing quality assurance portfolio, including the quality management standards ISO 9001:2008 and ISO 13485 and Good Clinical Laboratory Practice (GCLP).
Graham Mullis, CEO of Lab21, commented: “I am delighted that our laboratories in Cambridge have been awarded the extended CPA accreditation status. This award underlines the commitment that Lab21 and our staff have to the provision of a quality service.”
Mike Annable, Divisional Director of Lab21’s Clinical Laboratory division, added “CPA accreditation endorses the quality of our laboratory operations. Lab21 is committed to the provision of independently validated services that meet the requirements of the increasingly complex regulatory framework covering the use of in vitro diagnostics.”
For further information:
Graham Mullis, CEO
t: +44 (0)1223 395461
For media and investor enquiries:
Nicole Yost/Gemma Howe
t: +44 (0)20 7457 2020
Lab21 is a global leader in personalised healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations has a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley and Bridport. The Company's investors include Excalibur, Nexus Medical Partners and Medicis Capital. Website: www.lab21.com